This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chu, A. Articles by Cobb, F. R. Search for Related Content PubMed PubMed Citation Articles by Chu, A. Articles by Cobb, F. R.

Circulation, Vol 80, 1627-1635, Copyright © 1989 by American Heart Association

ARTICLES

Effects of atrial natriuretic peptide on the coronary arterial vasculature in humans [published erratum appears in Circulation 1990 Mar;81(3):1160]

A Chu, KG Morris, WD Kuehl, J Cusma, F Navetta and FR Cobb
Department of Medicine, Duke Medical Center, Durham, North Carolina.

The effects of the synthetic 28-amino-acid alpha-human atrial natriuretic peptide (ANP) on the proximal coronary arteries and coronary blood flow were evaluated in 17 patients. Proximal coronary dimension was quantitated by digital angiography, and coronary flow was quantitated with 3F Doppler flow catheters. ANP, when given as a 2.5- micrograms/kg bolus in the left ventricle, caused sustained significant proximal coronary dilations from 3.49 +/- 0.57 to 4.09 +/- 0.76 mm, lasting more than 30 minutes. The proximal coronary diameter did not increase further after intracoronary injection of 0.3 mg nitroglycerin (4.08 +/- 0.79 mm). Coronary flow (resistance coronary dilation) was not significantly increased at 5 minutes after ANP (87 +/- 55 to 102 +/- 54 vol flow units), indicating that the proximal coronary dilations were not flow dependent. The persistent proximal coronary dilations were associated with minor and transient decreases in aortic pressure and left ventricular end-diastolic pressure and with minor and transient increases in heart rate, cardiac output, and left ventricular contractility. Plasma ANP level increased significantly by more than sixfold from 39.8 +/- 8.8 to 245.8 +/- 168.5 pg/ml. The time course of proximal coronary dilations was related more closely to the time course of increase in plasma cyclic guanosine monophosphate than that of plasma ANP. This study demonstrates that bolus injection of ANP (2.5 micrograms/kg), an endogenous vasodilator, caused marked sustained preferential proximal coronary dilations and brief minor changes in cardiac and systemic hemodynamics. Although additional studies are needed to assess its clinical efficacy as a coronary dilator in the treatment of coronary artery disease, these data suggest a potential of ANP in the therapy of ischemia.

This article has been cited by other articles:

				W. W. Zhang, N. W. Hasaniya, S. Premaratne, and J. J. McNamara Atrial Natriuretic Peptide Protects Against Ischemia-Reperfusion Injury in Rabbit Hearts In Vivo Vascular and Endovascular Surgery, June 1, 2008; 42(3): 263 - 267. [Abstract] [PDF]

				T. Ashikaga, M. Nishizaki, H. Fujii, K. Ihara, S. Niki, T. Murai, S. Maeda, N. Yamawake, Y. Kishi, and M. Isobe Coronary Endothelial Dysfunction and Impaired Microcirculation Response to Atrial Natriuretic Peptide in Hyperinsulinemia Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2008; 13(1): 58 - 63. [Abstract] [PDF]

				A. Sezai, M. Shiono, Y. Orime, H. Hata, M. Hata, N. Negishi, and Y. Sezai Low-dose continuous infusion of human atrial natriuretic peptide during and after cardiac surgery Ann. Thorac. Surg., March 1, 2000; 69(3): 732 - 738. [Abstract] [Full Text] [PDF]

				A. L'Abbate, G. Sambuceti, S. Haunso, and J. Schneider-Eicke Methods for evaluating coronary microvasculature in humans Eur. Heart J., September 2, 1999; 20(18): 1300 - 1313. [PDF]

				T. Matsumoto, A. Wada, T. Tsutamoto, T. Omura, H. Yokohama, M. Ohnishi, I. Nakae, M. Takahashi, and M. Kinoshita Vasorelaxing effects of atrial and brain natriuretic peptides on coronary circulation in heart failure Am J Physiol Heart Circ Physiol, June 1, 1999; 276(6): H1935 - H1942. [Abstract] [Full Text] [PDF]

				F. Valsson, S. Lundin, K. Kirno, T. Hedner, E. Houltz, Y. Saito, and S.-E. Ricksten Atrial Natriuretic Peptide Attenuates Pacing-Induced Myocardial Ischemia During General Anesthesia in Patients with Coronary Artery Disease Anesth. Analg., February 1, 1999; 88(2): 279 - 279. [Abstract] [Full Text] [PDF]

				A D Struthers Fortnightly Review: Ten years of natriuretic peptide research: a new dawn for their diagnostic and therapeutic use? BMJ, June 18, 1994; 308(6944): 1615 - 1619. [Full Text]